U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C20H16N4O
Molecular Weight 328.3672
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of 4-(2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinolin-7-ol

SMILES

OC1=CC2=NC=CC(C3=C4CCCN4N=C3C5=NC=CC=C5)=C2C=C1

InChI

InChIKey=ZDNICFYNWASODE-UHFFFAOYSA-N
InChI=1S/C20H16N4O/c25-13-6-7-14-15(8-10-22-17(14)12-13)19-18-5-3-11-24(18)23-20(19)16-4-1-2-9-21-16/h1-2,4,6-10,12,25H,3,5,11H2

HIDE SMILES / InChI
Molecular Formula C20H16N4O
Molecular Weight 328.3672
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

TGF-B-recpotor inhibitor (dihydropyrrolopyrazole, 13) is one of the series of optimized, bioavailable dihydropyrrolopyrazole TGF-beta receptor type I inhibitors synthesized at Ely Lilly and is an investigational antitumor agent.

Originator

Eli Lilly
239
Curator's Comment: # Eli Lilly

Approval Year

Unknown
149124
Targets

Targets

Primary TargetPharmacologyConditionPotency
TGF-beta receptor type-1
8
Target ID: P36897
Gene ID: 7046.0
Gene Symbol: TGFBR1
Target Organism: Homo sapiens (Human)
Inhibitor
8504
 160.0 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
PubMed

PubMed

TitleDatePubMed
Optimization of a dihydropyrrolopyrazole series of transforming growth factor-beta type I receptor kinase domain inhibitors: discovery of an orally bioavailable transforming growth factor-beta receptor type I inhibitor as antitumor agent.
2008-04-10
Synthesis and activity of new aryl- and heteroaryl-substituted 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole inhibitors of the transforming growth factor-beta type I receptor kinase domain.
2004-07-05

Sample Use Guides

In Vivo Use Guide
Unknown
Route of Administration: Unknown
In Vitro Use Guide
Antiproliferative activity against mouse NIH3T3 cells by [3H]thymidine assay of TGF-B-recpotor inhibitor (compound 13) had IC50 of 420±410 nM. EC50 of 200±73 nM value was obtained from luciferase reporter assay in mink mink lung epithelial Mv1Lu p3TP-Lux stable transfectants.
Substance Class Chemical
Created
by admin
on Wed Apr 02 15:28:55 GMT 2025
Edited
by admin
on Wed Apr 02 15:28:55 GMT 2025
Record UNII
MT5X3CS22S
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
4-(2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinolin-7-ol
Systematic Name English
7-Quinolinol, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-
Preferred Name English
Code System Code Type Description
CAS
476474-11-0
Created by admin on Wed Apr 02 15:28:55 GMT 2025 , Edited by admin on Wed Apr 02 15:28:55 GMT 2025
PRIMARY
PUBCHEM
135506615
Created by admin on Wed Apr 02 15:28:55 GMT 2025 , Edited by admin on Wed Apr 02 15:28:55 GMT 2025
PRIMARY
FDA UNII
MT5X3CS22S
Created by admin on Wed Apr 02 15:28:55 GMT 2025 , Edited by admin on Wed Apr 02 15:28:55 GMT 2025
PRIMARY
EPA CompTox
DTXSID20433199
Created by admin on Wed Apr 02 15:28:55 GMT 2025 , Edited by admin on Wed Apr 02 15:28:55 GMT 2025
PRIMARY
Related Record Type Details
TGF-BETA RECEPTOR TYPE-1
TARGET -> INHIBITOR
IC50
Related Record Type Details
Structure of BR-007
PRODRUG -> METABOLITE ACTIVE
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966